TY - JOUR
T1 - Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis
AU - Feu, F.
AU - García-Pagán, J. C.
AU - Bosch, J.
AU - Luca, A.
AU - Escorsell, A.
AU - Rodés, J.
AU - Terés, J.
PY - 1995/10/21
Y1 - 1995/10/21
N2 - Summary. In patients with variceal bleeding as a complication of hepatic cirrhosis, propranolol therapy reduces the risk of recurrent variceal haemorrhage. However, the relation between portal pressure response to pharmacological treatment and clinical events has not been well defined. This relation was prospectively investigated in 69 cirrhotic patients receiving continued propranolol therapy after an episode of variceal bleeding. Hepatic venous pressure gradient (HVPG) was measured before and at 3 months of continued drug therapy. At 3 months HVPG had fallen by 20% or more in 25 patients. During follow-up of 28 (SD 17) months rebleeding occurred in 2 of these 25 patients compared with 23 of 44 who had lesser reductions in HVPG. Cumulative probability of rebleeding at 1, 2, and 3 years was 4%, 9%, and 9% in patients with a decrease in HVPG {succeeds or equal to}20%, and 28%, 39%, and 66% in patients with a decrease in HVPG
AB - Summary. In patients with variceal bleeding as a complication of hepatic cirrhosis, propranolol therapy reduces the risk of recurrent variceal haemorrhage. However, the relation between portal pressure response to pharmacological treatment and clinical events has not been well defined. This relation was prospectively investigated in 69 cirrhotic patients receiving continued propranolol therapy after an episode of variceal bleeding. Hepatic venous pressure gradient (HVPG) was measured before and at 3 months of continued drug therapy. At 3 months HVPG had fallen by 20% or more in 25 patients. During follow-up of 28 (SD 17) months rebleeding occurred in 2 of these 25 patients compared with 23 of 44 who had lesser reductions in HVPG. Cumulative probability of rebleeding at 1, 2, and 3 years was 4%, 9%, and 9% in patients with a decrease in HVPG {succeeds or equal to}20%, and 28%, 39%, and 66% in patients with a decrease in HVPG
UR - http://www.scopus.com/inward/record.url?scp=0028790232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028790232&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(95)91740-3
DO - 10.1016/S0140-6736(95)91740-3
M3 - Article
C2 - 7564785
AN - SCOPUS:0028790232
VL - 346
SP - 1056
EP - 1059
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 8982
ER -